$0.18
-0.03 (-14.90%)
Open$0.22
Previous Close$0.22
Day High$0.23
Day Low$0.17
52W High$2.40
52W Low$0.10
Volume—
Avg Volume443.1K
Market Cap2.99M
P/E Ratio—
EPS$-2.06
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+13,526.0% upside
Current
$0.18
$0.18
Target
$25.14
$25.14
$18.28
$25.14 avg
$30.13
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 204.9K | 501.7K | 427.8K |
| Net Income | -245,012,378 | -539,806,952 | 33.9K |
| Profit Margin | -119,566.5% | -113,588.2% | 7.9% |
| EBITDA | -244,197,285 | -567,900,662 | 68.2K |
| Free Cash Flow | — | — | 23.2K |
| Rev Growth | -59.2% | -59.2% | +6.7% |
| Debt/Equity | 0.00 | 0.00 | 0.27 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |